Erik C. BöttgerBurkhard SpringerTherdsak PrammanananYishak KidanPeter SanderMedizinische Hochschule Hannover (MHH)ETH ZurichMahidol University2018-09-072018-09-072001-05-15EMBO Reports. Vol.2, No.4 (2001), 318-3231469221X2-s2.0-0035032997https://repository.li.mahidol.ac.th/handle/20.500.14594/26464Ribosomal antibiotics must discriminate between bacterial and eukaryotic ribosomes to various extents. Despite major differences in bacterial and eukaryotic ribosome structure, a single nucleotide or amino acid determines the selectivity of drugs affecting protein synthesis. Analysis of resistance mutations in bacteria allows the prediction of whether cytoplasmic or mitochondrial ribosomes in eukaryotic cells will be sensitive to the drug. This has important implications for drug specificity and toxicity. Together with recent data on the structure of ribosomal subunits these data provide the basis for development of new ribosomal antibiotics by rationale drug design.Mahidol UniversityBiochemistry, Genetics and Molecular BiologyArticleSCOPUS10.1093/embo-reports/kve062